PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE MAR 2 2 2004 n Act of 1995, no p Under the Paperwork Red are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE Complete if Known Application Number 10/609,176 June 27, 2003 Filing Date STATEMENT BY APPLICANT Thomas J. Guttuso, Jr. First Named Inventor (use as many sheets as necessary) 1617 Art Unit S.A. Jiang Examiner Name Sheet of Attorney Docket Number 176/60807 (6-11406-955)

				U.S. PATENT DOC	CUMENTS	
Examiner Initials*		Cite No.'	U.S. Patent Document Number - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
S	G	1	US-5,344,830	09-06-1994	Mills et al.	
		2	US-5,554,627	09-10-1996	Lewis et al.	
		3	US-5,554,641	09-10-1996	Horwell et al.	
		4	US-5,563,161	10-08-1996	Huscroft et al.	
		5	US-5,594,022	01-14-1997	Horwell et al.	
		6	US-5,607,936	03-04-1997	Chiang et al.	
		7	US-5,610,145	03-11-1997	Horwell et al.	
		8	US-5,610,165	03-11-1997	MacCoss et al.	
		9	US-5,612,336	03-18-1997	Lewis et al.	
		10	US-5,624,947	04-29-1997	Keown et al.	
		11	US-5,627,211	05-06-1997	Teall et al.	
		12	US-5,633,266	05-27-1997	Baker et al.	
П		13	US-5,635,509	06-03-1997	Jacobs et al.	
		14	US-5,633,281	05-27-1997	Teall et al.	
\Box		15	US-5,654,316	08-05-1997	Carruthers et al.	
		16	US-5,663,352	09-02-1997	MacLeod et al.	
		17	US-5,665,883	09-09-1997	Baker et al.	
		18	US-5,688,960	11-18-1997	Shankar	
		19	US-5,969,123	12-09-1997	Dollinger et al.	
	-	20	US-5,696,267	12-09-1997	Reichard et al.	
		21	US-5,698,710	12-16-1997	Sisto et al.	
		22	US-5,708,006	01-13-1998	Dollinger et al.	
		23	US-5,719,156	02-17-1998	Shue et al.	
		24	US-5,731,309	03-24-1998	Bernstein et al.	
		25	US-5,760,018	06-02-1998	Baker et al.	
		26	US-5,760,248	06-02-1998	Sisto et al.	
		27	US-5,846,965	12-08-1998	MacKenzie et al.	
		28	US-5,849,795	12-15-1998	Sisto et al.	
		29	US-5,892,039	04-06-1999	Shue et al.	
		30	US-5,919,803	07-06-1999	Giblin et al.	
	/	31	US-5,922,744	07-13-1999	Harrison et al.	
┌₩		32	US-5,935,972	08-10-1999	Naylor et al.	
SC	3	33	US-5,945,428	08-31-1999	Shih et al.	

		FOI	REIGN PATENT I	OCUMENTS	
Examiner Initials	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cited Do	
		Country Code ³ Number (if known)			Figures Appear T ⁶
Examiner Signature		/Shirley Gembeh/		Date Considered	08/24/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222 uspto gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

176/60807 (6-11406-955)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/609,176 INFORMATION DISCLOSURE June 27, 2003 Filing Date STATEMENT BY APPLICANT Thomas J. Guttuso, Jr. First Named Inventor (use as many sheets as necessary) Art Unit S.A. Jiang Examiner Name

Attorney Docket Number

			U.S. PATENT DO	CUMENTS	
Examiner Initials*	Cite No. ³	U.S. Patent Document Number - Kind Code ² (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SG	34	US-5,962,485	10-05-1999	Owens	
	35	US-5,968,923	10-19-1999	MacKenzie et al.	
	36	US-5,968,929	10-19-1999	Blythin et al.	
	37	US-6,013,652	01-11-2000	Maccoss et al.	
	38	US-6,020,346	02-01-2000	Armour et al.	
	39	US-6,046,195	04-04-2000	Haworth et al.	
	40	US-6,060,469	05-09-2000	Baker et al.	
	41	US-6,063,926	05-16-2000	Reichard et al.	
	42	US-6,103,719	08-15-2000	Esser et al.	
	43	US-6,110,919	08-29-2000	Howard et al.	
	44	US-6,150,325	11-21-2000	Arcamone et al.	
	45	US-6,204,265 B1	03-20-2001	Reichard et al.	
	46	US-6,207,678 B1	03-27-2001	Monaghan et al.	
	47	US-6,242,438 B1	06-05-2001	MacKenzie et al.	
SG	48	US-6,235,732 B1	05-22-2001	Dollinger et al.	
	 	•			
	<u> </u>				
	-				
					<u> </u>

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Cohmms, Lines, Where Relevant Passages or Relevant Figures Appear	
		Country Code ³ Number ⁴ (if known)				т°
SG	49	WO 00/67742	11/16/2000	Magistro		

				_
Examiner Signature	/Shirley Gembeh/	Date Considered	08/24/2006	_

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Shect

of

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to respond to a collection of information unless it contains a valid OMB control number.

Substitute	Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			OSLIDE	Application Number	10/609,176	
				Filing Date	June 27, 2003	
SIAI				First Named Inventor	Thomas J. Guttuso, Jr.	
	(use as many sheets a	is necessa	(יציע	Group Art Unit	1617	
				Examiner Name	S.A. Jiang	
Sheet	3	of	4	Attorney Docket Number	176/60807 (6-11406-955)	

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.						
SG	50	Wallace et al., Org. Lett. 3(5):671-674 (2001)						
	51	Reichard et al., Bioorg. Med. Chem. Lett. 10(20):2329-2332 (2000)						
	52	Liu et al., J. Med. Chem. 43(21):3827-3831 (2000)						
	.53	Nishi et al., <u>Bioorg. Med. Chem. Lett.</u> 10(15):1665-668 (2000)						
	54	Rosen et al., <u>Bioorg. Med. Chem. Lett.</u> 8(3):281-284 (1998)						
	55	Caliendo et al., <u>Farmaco</u> 52(10):589-593 (1997)						
	56	Kubota et al., <u>Chem. Pharm. Bull. (Tokyo)</u> 46(2):351-354 (1998)						
	57	Hirschmann et al., <u>J. Med. Chem.</u> 39(13):2441-2448 (1996)						
	58	Caliendo et al., <u>Farmaco</u> 50(11):755-759 (1995)						
	59	Karagiannis et al., <u>Int. J. Pept. Protein Res.</u> 42(6):565-569 (1993)						
 	60	Rosen et al., <u>J. Med. Chem.</u> 36(21):3197-3201 (1993)						
SG	61	Caliendo et al., <u>Farmaco</u> 48(10):1359-1378 (1993)						

Examiner Signature	/Shirley Gembeh/	Date Considered	08/24/2006

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it contains a valid OMB control number

	for form 1449B/PTO			Complete if Known		
INFO	DMATION	DISC	ACIDE	Application Number	10/609,176	
INFORMATION DISCLOSURE				Filing Date	June 27, 2003	
SIAI	STATEMENT BY APPLICANT		First Named Inventor	Thomas J. Guttuso, Jr.		
	(use as many sheets	as necesso	(עיני	Group Art Unit	1617	
				Examiner Name	S.A. Jiang	
Sheet	4	of	4	Attorney Docket Number	176/60807 (6-11406-955)	

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner nitials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SG	62	Manolopoulou et al., Int. J. Pept. Protein Res. 41(4):411-414 (1993)	
SG	63	Lawrence et al., <u>J. Med. Chem.</u> 35(7):1273-1279 (1992)	
SG	64	Aitken et al., Bioorg. Med. Chem. Lett. 11(5):659-661 (2001)	
SG	65	Elling et al., <u>Biochemistry</u> 39(4):667-675 (2000)	
SG	66	Bryans et al., "3-Substituted GABA Analogs with Central Nervous System Activity: A Review," John Wiley & Sons, Inc. 29:149-177 (1999)	
SG	67	Guttuso, Jr., M.D., Thomas, "Gabapentin's Effects on Hot Flashes and Hypothermia," American Academy of Neurology 54:2161-2163 (2000)	
SG	68	Hardman et al., "Goodman & Gilman's The Pharmacological Basis of Therapeutics" (9th ed, 1996) page 51 and 57-58	
			1

Evamines	/Shirley Gembeh/	Date	ļ
Examiner	/ billing democil/	Date	00/04/0000
Signature	_	Considered	08/24/2006

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

			Co	Complete if Known		
ubdivite for form 1449A PTO			Application Number	10/609,176		
NFORMATION DISCLOSURE				June 27, 2003 Thomas J. Guttuso, Jr.		
STATEMENT BY APPLICANT		Filing Date				
	theets as necessa		First Named Inventor	1617		
(use as many :	meets us meets	-57	Art Unit	S.A. Jiang		
			Examiner Name Attorney Docket Number	176/60807 (6-11406-955)		
iheet i	of	11	Anomey Docker Number	170,00007 (6 10 10 17		

		·	U.S. PATENT DOCUM		
	Cite	U.S. Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant
initials"	No. ¹	Number - Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear
	+	US-			
		US-			
		US-			
	1	US-			
		US-			
	_	US-			
	$\neg \vdash \neg$	US-			

		FO	REIGN PATENT DO	CUMENIS	1	
Examiner nitials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Cohumns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
muas		Country Code ³ Number ⁴ (If known)	Man-DD-1111			
				TO CHARLES TO		<u> </u>
				TERATURE DOCUMENTS		T ²
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.				
SG	1	Fisher et al., "Tachykinin Receptors Mediating Contractions of Oestrogen-Primed Rat Uterus: Classification Using Non-Peptide Antagonists," Clinical and Experimental Pharmacology and Physiology 26:729-735 (1999)				
SG	2	Moodley et al., "NK ₂ Receptors Mediate Tachykinin-Induced Contractions of Rat Uterus During the Oestrous Cycle," European Journal of Pharmacology 376:53-60 (1999)				

				
			Date	00/04/0006
1	Examiner	/Shirley Gembeh/	Considered	08/24/2006
	Signature	/SHITTEY GEMMENT		The showest situation if not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is

·		Sheet 1 of 2
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE	176/60807 (6-11405-955)	CON of 09/879,390
STATEMENT BY APPLICANT	APPLICANT	
(use several sheets if necessary)	Thomas J. Guttuso, Jr.	
(PTO-1449)	FILING DATE	GROUP ART UNIT
(P10-1449)	Herewith	

U.S. PATENT DOCUMENTS

		,	 <u> </u>	PRIATE
SG 1 5,744,156 Ú	-28-98	De Lacharriere et al.		

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE
SG	2	WO 99/09987	03/04/99	WIPO		 	
SG	3	WO 98/43639	10/08/98	WIPO		<u></u>	
SG	4	WO 96/24353	08/15/96	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

SG		5	Hay, "Chronic Obstructive Pulmonary Disease: Emerging"	Therapies," Current Opinion in Chemical Biology 4:412-419			
(2000)							
	6 Abraham et al., "Cancer Chemotherapy and Radiation Induced Emesis (CRIE): Current and Future Therapeutic A						
SG			Indian Journal of Pharmacology 32:256-268 (2000)				
		7	Von Sprecher et al., "Neurokinin Antagonists as Potential T	herapies for Inflammation and Rheumatoid Arthritis,"			
SG			ldrugs 1(1):73-91 (1998)				
SG Rance et al., "Hypertrophy and Increased Gene Expression of Neurons Containing Neurokinin-B and S Ribonucleic Acids in the Hypothalami of Postmenopausal Women," Endocrinology 128(5):2239-2247		of Neurons Containing Neurokinin-B and Substance-P Messenger					
			Ribonucleic Acids in the Hypothalami of Postmenopausal Women,* Endocrinology 128(5):2239-2247 (1991)				
		9	Casper et al., "Menopausal Flushes: A Neuroendocrine Link with Pulsatile Luteinizing Hormone Secretion,"				
SG			<u>Science</u> 205:823-825 (1979)				
		10	Norheim et al., "Tachykinins in Carcinoid Tumors: Their I	Ise as a Tumor Marker and Possible Role in the Carcinoid Flush,"			
SG			Journal of Clinical Endocrinology and Metabolism 63(3):605-612 (1986)				
		Conlon et al., "Circulating Tachykinins (Substance P, Neurokinin A, Neuropeptide K) and the Carcinoid Flush,"		okinin A, Neuropeptide K) and the Carcinoid Flush,"			
SG			Şcand, J, Gastroenterol, 22: 97-105 (1986)				
		12	Öberg et al., "The Effects of Octreotide on Basal and Stimu	lated Hormone Levels in Patients with Carcinoid Syndrome,"			
SG			Journal of Clinical Endocrinology and Metabolism 68(4):79	5-800 (1989)			
EXAMINE	EXAMINER /Shirley Gembeh/ DATE CONSIDERED 08/24/2006						

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

not considered. Include copy of this form with next communication to applicant.